Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Announces Exercise of Warrants for EUR EUR 884,476.40
Ablynx NV announced that an additional 273,913 common shares have been issued by the Company in exchange for EUR 884,476.40 as the result of the exercise of warrants by some employees and consultants of the Company. As a result of this transaction, Ablynx NV has 48,802,115 shares outstanding.
Latest Developments for Ablynx NV
Latest Key Developments in Biotechnology
- European Medicines Agency issues positive opinion, recommends full approval of Pharmacyclics Inc's Imbruvica for treatment of two blood cancers
- CanTx Inc and Novogen Ltd appoints contract manufacturing organizations to produce clinical batches of the experimental anti cancer drug
- Zhongyuan Union Stem Cell Bioengineering Co to set up joint venture
- Applied Genetic Technologies Crop announces pricing of public offering
- Share this
- Digg this